Biological response of adrenal carcinoma and melanoma cells to mitotane treatment.
adrenocortical carcinoma
melanoma metastasis
mitotane
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
31
07
2021
accepted:
02
12
2021
entrez:
9
3
2022
pubmed:
10
3
2022
medline:
10
3
2022
Statut:
ppublish
Résumé
A previous case report described an adrenal incidentaloma initially misdiagnosed as adrenocortical carcinoma (ACC), which was treated with mitotane. The final diagnosis was metastatic melanoma of unknown primary origin. However, the patient developed rapid disease progression after mitotane withdrawal, suggesting a protective role for mitotane in a non-adrenal-derived tumor. The aim of the present study was to determine the biological response of primary melanoma cells obtained from that patient, and that of other established melanoma and ACC cell lines, to mitotane treatment using a proliferation assay, flow cytometry, quantitative PCR and microarrays. Although mitotane inhibited the proliferation of both ACC and melanoma cells, its role in melanoma treatment appears to be limited. Flow cytometry analysis and transcriptomic studies indicated that the ACC cell line was highly responsive to mitotane treatment, while the primary melanoma cells showed a moderate response
Identifiants
pubmed: 35261634
doi: 10.3892/ol.2022.13240
pii: OL-23-04-13240
pmc: PMC8855164
doi:
Types de publication
Journal Article
Langues
eng
Pagination
120Informations de copyright
Copyright: © Stelcer et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Eur J Endocrinol. 2013 Oct 23;169(6):891-899
pubmed: 24086089
Int J Oncol. 2019 Jun;54(6):2149-2156
pubmed: 30942448
Bioinformatics. 2004 Feb 12;20(3):307-15
pubmed: 14960456
Clin Trials. 2020 Jun;17(3):285-294
pubmed: 32063031
Bioinformatics. 2010 Oct 1;26(19):2363-7
pubmed: 20688976
Int J Oncol. 2010 Aug;37(2):493-501
pubmed: 20596677
Front Endocrinol (Lausanne). 2017 Feb 15;8:26
pubmed: 28261157
Transl Oncol. 2017 Feb;10(1):22-32
pubmed: 27888710
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Endokrynol Pol. 2014;65(6):492-502
pubmed: 25554619
J Pharm Pharmacol. 2017 Nov;69(11):1524-1530
pubmed: 28809444
Clin Cancer Res. 2012 Jun 15;18(12):3452-61
pubmed: 22547773
J Biol Chem. 2015 Apr 24;290(17):11108-18
pubmed: 25770212
Int J Mol Sci. 2019 Oct 30;20(21):
pubmed: 31671654
Medicine (Baltimore). 2020 Oct 2;99(40):e22620
pubmed: 33019484
Mol Med Rep. 2013 Mar;7(3):893-900
pubmed: 23254310
Oncotarget. 2018 Jan 9;9(6):6977-6992
pubmed: 29467944
IUBMB Life. 2015 Feb;67(2):77-87
pubmed: 25855199
J Clin Aesthet Dermatol. 2014 Jun;7(6):13-24
pubmed: 25013535
Arch Biochem Biophys. 2020 Dec 15;696:108668
pubmed: 33188737
Cancers (Basel). 2019 Nov 09;11(11):
pubmed: 31717612
Int J Oncol. 2019 Jul;55(1):7-20
pubmed: 31115496
J Endocrinol Invest. 2020 Mar;43(3):357-367
pubmed: 31587178
Front Cell Dev Biol. 2015 Jul 03;3:45
pubmed: 26191527
Database (Oxford). 2017 Jan 6;2017:
pubmed: 28062517
Nat Genet. 2004 Jul;36(7):663; author reply 663
pubmed: 15226741
Biostatistics. 2017 Jan;18(1):91-104
pubmed: 27445132
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Oncotarget. 2017 Jul 10;8(37):62167-62182
pubmed: 28977935
J Clin Endocrinol Metab. 2015 Aug;100(8):2890-8
pubmed: 26120791
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560
pubmed: 31114875
Endocr Rev. 2014 Apr;35(2):282-326
pubmed: 24423978
Mol Cell Biol. 2001 Apr;21(8):2755-66
pubmed: 11283255
J Invest Dermatol. 2012 Feb;132(2):356-64
pubmed: 21993556
Genome Biol. 2003;4(5):P3
pubmed: 12734009
Pediatr Blood Cancer. 2006 Jul;47(1):56-60
pubmed: 16200634
Endocr Connect. 2020 Feb;9(2):122-134
pubmed: 31910152
F1000Res. 2014 Jul 01;3:141
pubmed: 25075306
Endocr Relat Cancer. 2013 Jun 27;20(4):537-50
pubmed: 23722227
Bio Protoc. 2019 Jan 5;9(1):
pubmed: 30687773
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Bioinformatics. 2013 Nov 1;29(21):2810-1
pubmed: 23958726
Endocrinology. 2015 Nov;156(11):3895-908
pubmed: 26305886
Pharmacogenomics. 2012 Sep;13(12):1351-61
pubmed: 22966885
J Clin Endocrinol Metab. 2008 Nov;93(11):4542-6
pubmed: 18713819
Am J Med. 2020 Sep;133(9):1048-1050
pubmed: 32001227
PLoS One. 2014 Mar 12;9(3):e91771
pubmed: 24622579
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
F1000Res. 2016 Jul 15;5:1717
pubmed: 27830058
Endokrynol Pol. 2020;71(6):575-576
pubmed: 32944927
Cell Rep. 2014 May 8;7(3):645-53
pubmed: 24746818
Cancer Cell Int. 2020 Apr 15;20:123
pubmed: 32322170
Eur Endocrinol. 2018 Sep;14(2):62-66
pubmed: 30349596
Clinics (Sao Paulo). 2018 Dec 10;73(suppl 1):e756s
pubmed: 30540124
Oncol Rep. 2019 Sep;42(3):1017-1034
pubmed: 31322267
J Clin Oncol. 2015 Feb 20;33(6):602-9
pubmed: 25584008
Bioinformatics. 2015 Sep 1;31(17):2912-4
pubmed: 25964631
Front Endocrinol (Lausanne). 2020 Oct 08;11:561370
pubmed: 33133015
Am J Transl Res. 2020 May 15;12(5):1614-1639
pubmed: 32509165
Small GTPases. 2012 Oct-Dec;3(4):225-8
pubmed: 22735340
Mol Cell Endocrinol. 2012 Mar 31;351(1):58-65
pubmed: 21924324
Molecules. 2019 Jun 12;24(12):
pubmed: 31212829
Oncotarget. 2017 Jul 4;8(66):109924-109940
pubmed: 29299119